WO2005072719A8 - Medicinal acidic cannabinoids - Google Patents

Medicinal acidic cannabinoids

Info

Publication number
WO2005072719A8
WO2005072719A8 PCT/NL2005/000075 NL2005000075W WO2005072719A8 WO 2005072719 A8 WO2005072719 A8 WO 2005072719A8 NL 2005000075 W NL2005000075 W NL 2005000075W WO 2005072719 A8 WO2005072719 A8 WO 2005072719A8
Authority
WO
WIPO (PCT)
Prior art keywords
medicinal
acid
acidic cannabinoid
acidic
cbd
Prior art date
Application number
PCT/NL2005/000075
Other languages
French (fr)
Other versions
WO2005072719A1 (en
Inventor
Henricus Adriaan Anne Korthout
Kitty Catharina Mari Verhoeckx
Rentje Frederik Witkamp
Robert Paul Doornbos
Mei Wang
Original Assignee
Tno
Henricus Adriaan Anne Korthout
Kitty Catharina Mari Verhoeckx
Rentje Frederik Witkamp
Robert Paul Doornbos
Mei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno, Henricus Adriaan Anne Korthout, Kitty Catharina Mari Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang filed Critical Tno
Priority to ES05704605T priority Critical patent/ES2375362T3/en
Priority to EP05704605A priority patent/EP1893191B1/en
Priority to AT05704605T priority patent/ATE527995T1/en
Publication of WO2005072719A1 publication Critical patent/WO2005072719A1/en
Publication of WO2005072719A8 publication Critical patent/WO2005072719A8/en
Priority to IL177219A priority patent/IL177219A/en
Priority to US11/461,818 priority patent/US7807711B2/en
Priority to US12/862,865 priority patent/US20110021617A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.
PCT/NL2005/000075 2004-02-02 2005-02-02 Medicinal acidic cannabinoids WO2005072719A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES05704605T ES2375362T3 (en) 2004-02-02 2005-02-02 CANNABINOID MEDICINAL ACIDS.
EP05704605A EP1893191B1 (en) 2004-02-02 2005-02-02 Medicinal acidic cannabinoids
AT05704605T ATE527995T1 (en) 2004-02-02 2005-02-02 MEDICAL ACID CANNABINOIDS
IL177219A IL177219A (en) 2004-02-02 2006-08-01 Medicinal acidic cannabinoids
US11/461,818 US7807711B2 (en) 2004-02-02 2006-08-02 Medicinal acidic cannabinoids
US12/862,865 US20110021617A1 (en) 2004-02-02 2010-08-25 Medicinal Acidic Cannabinoids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04075300.6 2004-02-02
EP04075300A EP1559423A1 (en) 2004-02-02 2004-02-02 Medicinal acidic cannabinoids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/461,818 Continuation US7807711B2 (en) 2004-02-02 2006-08-02 Medicinal acidic cannabinoids

Publications (2)

Publication Number Publication Date
WO2005072719A1 WO2005072719A1 (en) 2005-08-11
WO2005072719A8 true WO2005072719A8 (en) 2005-10-27

Family

ID=34639453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2005/000075 WO2005072719A1 (en) 2004-02-02 2005-02-02 Medicinal acidic cannabinoids

Country Status (6)

Country Link
US (2) US7807711B2 (en)
EP (2) EP1559423A1 (en)
AT (1) ATE527995T1 (en)
ES (1) ES2375362T3 (en)
IL (1) IL177219A (en)
WO (1) WO2005072719A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
DE102007046086A1 (en) * 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Plant extract from THC-poor cannabis for the treatment of diseases
WO2010150245A1 (en) * 2009-06-24 2010-12-29 Tikun Olam Ltd. Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts
EP3834869A1 (en) 2010-12-22 2021-06-16 Syqe Medical Ltd. System for drug delivery
NL2006621C2 (en) 2011-04-18 2012-10-22 Fytagoras B V New medical use for acidic cannabinoids.
KR101943821B1 (en) * 2011-06-21 2019-01-31 한국전자통신연구원 Methods for transmitting and receiving of control channel in wireless communication systems
EP2760444B1 (en) 2011-09-29 2020-04-22 THC Pharm GmbH The Health Concept Cannabinoid carboxylic acids, salts of cannabinoid carboxylic acids, and the production and uses of same
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US20130274321A1 (en) * 2012-03-30 2013-10-17 Jon Newland Topical Compositions with Cannabis Extracts
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
US20160108016A1 (en) 2012-09-06 2016-04-21 Northeastern University Novel Cannabinergic Compounds and Uses Thereof
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
KR101892078B1 (en) * 2012-10-24 2018-08-28 한국해양과학기술원 Pharmaceutical Composition for Prevention or Treatment of Brain Cancer Comprising Robarstin and Combination Therapy in the Treatment of Brain Cancer Using the Same
US20140176689A1 (en) * 2012-12-21 2014-06-26 Samsung Electronics Co. Ltd. Apparatus and method for assisting the visually impaired in object recognition
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
US9199960B2 (en) * 2013-05-02 2015-12-01 Frederick R. Ferri Method and apparatus for processing herbaceous plant materials including the cannabis plant
US9333229B2 (en) 2013-10-16 2016-05-10 William Bjorncrantz Winterized crude cannabis extracts and methods of preparation and use
US9597279B2 (en) 2014-02-28 2017-03-21 HDDC Holdings, LLC Anti-aging dermal composition comprising herbal extracts
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
MX2017000056A (en) 2014-06-30 2017-06-30 Syqe Medical Ltd Flow regulating inhaler device.
MX2017000057A (en) 2014-06-30 2017-06-30 Syqe Medical Ltd Method and device for vaporization and inhalation of isolated substances.
PL3160552T3 (en) 2014-06-30 2020-03-31 Syqe Medical Ltd. Drug dose cartridge for an inhaler device
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
AU2015369546A1 (en) 2014-12-21 2017-07-13 One World Cannabis Ltd Cannabis-based extracts and topical formulations for use in skin disorders
EP3061450A1 (en) 2015-02-26 2016-08-31 Symrise AG Mixtures of cannabinoid compounds, their preparation and use
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
CA3003120A1 (en) * 2015-10-26 2017-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoid formulations
EP3399972B1 (en) 2016-01-06 2021-03-31 Syqe Medical Ltd. Low dose therapeutic treatment
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3031811A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018144637A1 (en) * 2017-02-01 2018-08-09 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
WO2018163163A1 (en) 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating inflammatory diseases
AU2018239671A1 (en) 2017-03-24 2019-10-10 Trait Biosciences, Inc. High level In vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems
CN111465700A (en) * 2017-07-11 2020-07-28 特征生物科学公司 Water soluble cannabinoid compounds and material compositions in yeast and plant cell suspension cultures
US11946059B2 (en) 2017-07-11 2024-04-02 Trait Biosciences, Inc. In vivo generation of water-soluble cannabinoids in plant cell suspension cultures
US11905543B2 (en) 2017-07-11 2024-02-20 Trait Biosceinces, Inc. In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures
EP3678658A4 (en) * 2017-09-08 2021-05-05 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and spilanthol
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3752231A4 (en) * 2018-02-15 2022-01-19 Syqe Medical Ltd. Method and inhaler for providing two or more substances by inhalation
CN112969452A (en) * 2018-04-09 2021-06-15 艾乐文特科学公司 Cannabis sativa extract for treating animal pain
US11351212B2 (en) * 2018-06-18 2022-06-07 Eric Young Method of drying botanicals
US20210315837A1 (en) * 2018-09-05 2021-10-14 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
CA3132856A1 (en) * 2019-04-30 2020-11-05 Elliot Altman Cannabinoid compositions and methods of using
EP4110045A1 (en) * 2020-02-25 2023-01-04 The Queen's Medical Center Cannabinoid compositions
WO2021188983A1 (en) * 2020-03-20 2021-09-23 The Queen's Medical Center Cannabinoid compositions
IL296892A (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847290A (en) 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
JP2000078979A (en) * 1998-09-04 2000-03-21 Taisho Pharmaceut Co Ltd Tetrahydrocannabinolic acid synthase gene
US6730519B2 (en) * 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
DE10051427C1 (en) * 2000-10-17 2002-06-13 Adam Mueller Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions

Also Published As

Publication number Publication date
EP1559423A1 (en) 2005-08-03
US20110021617A1 (en) 2011-01-27
WO2005072719A1 (en) 2005-08-11
EP1893191B1 (en) 2011-10-12
US20070032544A1 (en) 2007-02-08
ATE527995T1 (en) 2011-10-15
IL177219A0 (en) 2006-12-10
EP1893191A1 (en) 2008-03-05
IL177219A (en) 2013-12-31
US7807711B2 (en) 2010-10-05
ES2375362T3 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
WO2005072719A8 (en) Medicinal acidic cannabinoids
NZ735216A (en) Oral solid cannabinoid formulations, methods for producing and using thereof
Xiao et al. Molecular docking, kinetics study, and structure–activity relationship analysis of quercetin and its analogous as Helicobacter pylori urease inhibitors
Libro et al. Natural phytochemicals in the treatment and prevention of dementia: An overview
Vauzour et al. The neuroprotective potential of flavonoids: a multiplicity of effects
CA2582289C (en) Inhibition of tumour cell migration
Omar et al. Identification of proanthocyanidin dimers and trimers, flavone C-glycosides, and antioxidants in Ficus deltoidea, a Malaysian herbal tea
Fraga et al. Basic biochemical mechanisms behind the health benefits of polyphenols
Taschwer et al. Determination of the relative percentage distribution of THCA and Δ9-THC in herbal cannabis seized in Austria–Impact of different storage temperatures on stability
WO2009125198A3 (en) Cannabis sativa piants rich in cannabi chromene and its acid, extracts thereof and methods of obtaining extracts therefrom
Xiao et al. Noncovalent interaction of dietary polyphenols with bovine hemoglobin in vitro: Molecular structure/property–affinity relationship aspects
Sumbul et al. Role of phenolic compounds in peptic ulcer: An overview
Sharifzadeh et al. The effect of green tea extract on oxidative stress and spatial learning in streptozotocin-diabetic rats
Gentile et al. Polymeric proanthocyanidins from Sicilian pistachio (Pistacia vera L.) nut extract inhibit lipopolysaccharide-induced inflammatory response in RAW 264.7 cells
AU2002218242A1 (en) Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
Arimboor et al. Tetrahydroamentoflavone (THA) from Semecarpus anacardium as a potent inhibitor of xanthine oxidase
HUP0303002A3 (en) Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
Bitto et al. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions
EP2609928A3 (en) Use of cannabinoids in combination with an anti-psychotic medicament
MXPA05001621A (en) Improvements in the extraction of pharmaceutically active components from plant materials.
NO20062355L (en) Compositions for the treatment of oral cavity disease and upper respiratory system
NO20063655L (en) Formulation for the treatment of obesity and associated metabolic syndrome
Luño et al. Antioxidant effect of lemon balm (Melissa officinalis) and mate tea (Ilex paraguensys) on quality, lipid peroxidation and DNA oxidation of cryopreserved boar epididymal spermatozoa
Bidone et al. Antiherpes activity and skin/mucosa distribution of flavonoids from achyrocline satureioides extract incorporated into topical nanoemulsions
Jaisupa et al. Mangosteen peel extract exhibits cellular antioxidant activity by induction of catalase and heme oxygenase‐1 mRNA expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2005 UNDER (71) THE NAME SHOULD READ "NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO"

WWE Wipo information: entry into national phase

Ref document number: 177219

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11461818

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005704605

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11461818

Country of ref document: US